Enzymotec targets heart health market

- Last updated on GMT

Related tags: Heart health, Nutrition

Israeli nutritional oils company Enzymotec is launching a new heart
health brand, ArteriCare, which it claims offers superior
protection against cardiovascular disorders than many of the
phytosterol products currently available to consumers.

ArteriCare is based on the company's MultOil platform, a technology that modifies oils from soy, olives, milk fat or canola, to produce a product rich in phytosterol esters (25 per cent) and diglycerides (15 per cent).

"ArteriCare addresses those who suffer or are at high risk of cardiovascular disease, and up until recently could only benefit from partial solutions or were required to purchase a variety of different supplements,"​ said Dr Katz, Enzymotec's CEO.

"While other phytosterol-based products offer only reduction in cholesterol levels, ArteriCare simultaneously fights several major causes of CVD,"​ he said.

The company says it has found the Multoil products to both reduce total blood cholesterol levels and triglyceride levels. They have also been shown to act as an antioxidant and reduce blood serum oxidation levels, although the firm has not yet elucidated the actions behind this mechanism.

The first human clinical trial on the Multoil platform products is currently underway at the McGill University in Canada, with results expected in coming months.

Heart health is the second biggest driver of functional food purchases in Europe behind gut health, according to Datamonitor, and in the UK alone during 2002, heart health products generated 100 million pounds. Enzymotec says it is aiming for sales of $0.5 million for its Multoil products this year.

Related news

Show more

Related products

show more

Follow us


View more